Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Portfolio Pulse from Lara Goldstein
Portugal has decriminalized synthetic drugs, potentially impacting the global market for such substances. Clinical trials show promising results for psilocybin therapy in treating anorexia, with COMPASS Pathways' synthetic psilocybin COMP360 treatment showing potential. MindBio Therapeutics Corp. is recruiting participants for a clinical trial using LSD microdosing for cancer patients with emotional distress. California's TREAT initiative proposes a $5 billion state agency to fund and promote psychedelics research. The AdvisorShares Psychedelics ETF (PSIL) showed a slight uptake in the past week.
August 04, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
COMPASS Pathways' synthetic psilocybin COMP360 treatment shows promise as a therapy for anorexia nervosa.
The positive results from the clinical trial could increase investor confidence in COMPASS Pathways and its psilocybin therapy, potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The AdvisorShares Psychedelics ETF (PSIL) showed a slight uptake in the past week.
The slight uptake in PSIL's price indicates a positive market sentiment towards the psychedelics sector, which could potentially drive the ETF's price up.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100